Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: Promoting the early detection of hepatocellular carcinoma in China

BioScience Trends

Volumn 7, Issue 1, 2013, Pages 1-6

  Song, Peipei ^a   Feng, Xiaobin ^b   Zhang, Keming ^c   Song, Tianqiang ^d   Ma, Kuansheng ^b   Kokudo, Norihiro ^a   Dong, Jiahong ^e   Yao, Linong ^f   Tang, Wei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c BEIJING 302 HOSPITAL   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

fetoprotein (AFP); Des carboxyprothrombin (DCP); Guideline; Hepatitis B (hepB) immunization; Hepatitis B virus (HBV)

Indexed keywords

ARTICLE; CHINA; EARLY DIAGNOSIS; EPIDEMIOLOGICAL MONITORING; HEPATITIS B; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER TUMOR; METHODOLOGY;

CARCINOMA, HEPATOCELLULAR; CHINA; EARLY DETECTION OF CANCER; EPIDEMIOLOGICAL MONITORING; HEPATITIS B; HUMANS; JAPAN; LIVER NEOPLASMS;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84875931959     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2013.v7.1.1     Document Type: Article

References (48)

1. International Agency for Research on Cancer. Cancer incidence and mortality worldwide in 2008 (GLOBOCAN 2008). http://globocan.iarc.fr/factsheets/cancers/liver.asp (accessed November 10, 2012).
2. Yuen MF, Hou JL, Chutaputti A. Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009; 24:346-353.
3. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures. J Epidemiol. 2011; 21:401-416.
4. The Ministry of Health of the People's Republic of China. 2011 Chinese Health Statistics Yearbook (Section 9-3-1). http://61.49.18.65/htmlfiles/zwgkzt/ptjnj/year2011/index2011.html (accessed November 15, 2012).
5. Chinese Anti-Cancer Association Society of Liver Cancer, Chinese Society of Clinical Oncology, Chinese Society of Hepatology Liver Cancer Study Group. The expert consensus on the treatment standards for hepatocellular carcinoma. Digestive Disease and Endoscopy. 2009; 3:40-51. (in Chinese).
6. Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, Izumi N, Park JW, Poon RT, Sakamoto M. Liver Cancer Working Group report. Jpn J Clin Oncol. 2010; 40 (Suppl 1):i19-i27.
7. Gao JJ, Song PP, Tamura S, Hasegawa K, Sugawara Y, Kokudo N, Uchida K, Orii R, Qi FH, Dong JH, Tang W. Standardization of perioperative management on hepato-biliary-pancreatic surgery. Drug Discov Ther. 2012; 1:108-111.
8. Song PP, Kokudo N, Tang W. Des-γ-carboxyprothrombin: The evaluation on screening for and early diagnosis of HCC in China. The 8th International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences. February 1-2, 2013. Tokyo, Japan.
9. Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: A comparison of guidelines from 2001 to 2011. Liver Int. 2012; 32:1053-1063.
10. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology. 2000; 31:330-335.
11. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut. 2001; 48:251-259.
12. Danta M, Barnes E, Dusheiko G. The surveillance and diagnosis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2005; 17:491-496.
13. Elgouhari HM, Abu-Rajab Tamimi TI, Carey WD. Hepatitis B virus infection: Understanding its epidemiology, course, and diagnosis. Cleve Clin J Med. 2008; 75:881-889.
14. Song PP, Gao JJ, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: Evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China. Liver Cancer. 2013; 2:31-39.
15. Song PP, Gao JJ, Kokudo N, Dong JH, Tang W. "Knowledge into action" Exploration of an appropriate approach for constructing evidence-based clinical practice guidelines for hepatocellular carcinoma. Biosci Trends. 2012; 6:147-152.
16. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005; 42:1208-1236.
17. Ryder SD. British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003; 52 (Suppl 3):iii1-iii8.
18. Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: The J-HCC guidelines. J Gastroenterol. 2009; 44 (Suppl 19):119-121.
19. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, Yamaoka Y. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008; 38:37-51.
20. Kudo M, Okanoue T, Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007; 72 (Suppl 1):2-15.
21. Song PP, Tang W, Tamura S, Hasegawa K, Sugawara Y, Dong JH, Kokudo N. The management of hepatocellular carcinoma in Asia: A guideline combining quantitative and qualitative evaluation. Biosci Trends. 2010; 4:283-287.
22. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma - The Japan Society of Hepatology 2009 update. Hepatol Res. 2010; 40 (Suppl 1):2-144.
23. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011; 29:339-364.
24. Kokudo N, Sasaki Y, Nakayama T, Makuuchi M. Dissemination of evidence-based clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists, liver surgeons and primary care physicians. Gut. 2007; 56:1020-1021.
25. Kudo M. Real practice of hepatocellular carcinoma in Japan: Conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology. 2010; 78 (Suppl 1): 180-188.
26. Chen TH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, Yang PM, Lee HS, Duffy SW. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002; 98:257-261.
27. Tanaka J, Yoshizawa H. A national project for the management of viral hepatitis toward prevention of hepatocellular carcinoma in Japan. Gan To Kagaku Ryoho. 2004; 31:864-870. (in Japanese).
28. Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology. 2006; 49:7-17.
29. Izumi N. Diagnostic and treatment algorithm of the Japanese society of hepatology: A consensus-based practice guideline. Oncology. 2010; 78 (Suppl 1):78-86.
30. Chinese Center for Disease Control and Prevention. Nationwide hepatitis B virus seroepidemiological survey results. http://www.chinacdc.cn/n272442/n272530/n3246177/23316.html (accessed December 10, 2012).
31. Chinese Society of Hepatology in Chinese Medical Association, Chinese Society of Infectious Diseases in Chinese Medical Association. Chinese chronic hepatitis B prevention and cure guideline. Chinese Journal of Gastroenterology. 2011; 16:351-366. (in Chinese).
32. The Ministry of Health of the People's Republic of China. 2006-2010 National Hepatitis B Prevention and Control Plan. http://www.moh.gov.cn/mohbgt/pw10603/200804/27587.shtml (accessed December 15, 2012).
33. Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012; 9:CD002799.
34. Amarapurkar D, Han KH, Chan HL, Ueno Y. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J Gastroenterol Hepatol. 2009; 24:955-961.
35. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130:417-422.
36. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005; 9:235-251, vi.
37. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: A systematic review. Am J Gastroenterol. 2006; 101:513-523.
38. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S108-S112.
39. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol. 2006; 101:524-532.
40. Eleftheriou N, Heathcote J, Thomas HC, Sherlock S. Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma. J Clin Pathol. 1977; 30:704-708.
41. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: A comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007; 3:79-87.
42. Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 2008; 8:200.
43. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137:110-118.
44. Tang W. The diagnosis on liver cancer in China: Current status and evaluation on PIVKA-II. The 29th Inuyama Symposium. August 2-3, 2012. Inuyama, Japan.
45. Inagaki Y, Tang W, Xu H, Wang F, Nakata M, Sugawara Y, Kokudo N. Des-gamma-carboxyprothrombin: Clinical effectiveness and biochemical importance. Biosci Trends. 2008; 2:53-60.
46. Inagaki Y, Qi F, Gao J, Qu X, Hasegawa K, Sugawara Y, Tang W, Kokudo N. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends. 2011; 5:52-56.
47. Gao JJ, Inagaki Y, Xue X, Qu XJ, Tang W. c-Met: A potential therapeutic target for hepatocellular carcinoma. Drug Discov Ther. 2011; 5:2-11.
48. Gao J, Feng X, Inagaki Y, Song P, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Biosci Trends. 2012; 6:153-159.